2
|
Xiao H, Zhang M, Wu H, Wu J, Hu X, Pei X, Li D, Zhao L, Hua Q, Meng B, Zhang X, Peng L, Cheng X, Li Z, Yang W, Zhang Q, Zhang Y, Lu Y, Pan Z. CIRKIL Exacerbates Cardiac Ischemia/Reperfusion Injury by Interacting With Ku70. Circ Res 2022; 130:e3-e17. [PMID: 35105170 DOI: 10.1161/circresaha.121.318992] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Ku70 participates in several pathological processes through mediating repair of DNA double-strand breaks. Our previous study has identified a highly conserved long noncoding RNA cardiac ischemia reperfusion associated Ku70 interacting lncRNA (CIRKIL) that was upregulated in myocardial infarction. The study aims to investigate whether CIRKIL regulates myocardial ischemia/reperfusion (I/R) through binding to Ku70. METHODS CIRKIL transgenic and knockout mice were subjected to 45-minute ischemia and 24-hour reperfusion to establish myocardial I/R model. RNA pull-down and RNA immunoprecipitation assay were used to detect the interaction between CIRKIL and Ku70. RESULTS The expression of CIRKIL was increased in I/R myocardium and H2O2-treated cardiomyocytes. Overexpression of CIRKIL increased the expression of γH2A.X, a specific marker of DNA double-strand breaks and aggravated cardiomyocyte apoptosis, whereas knockdown of CIRKIL produced the opposite changes. Transgenic overexpression of CIRKIL aggravated cardiac dysfunction, enlarged infarct area, and worsened cardiomyocyte damage in I/R mice. Knockout of CIRKIL alleviated myocardial I/R injury. Mechanistically, CIRKIL directly bound to Ku70 to subsequently decrease nuclear translocation of Ku70 and impair DNA double-strand breaks repair. Concurrent overexpression of Ku70 mitigated CIRKIL overexpression-induced myocardial I/R injury. Furthermore, knockdown of human CIRKIL significantly suppressed cell damage induced by H2O2 in adult human ventricular cardiomyocytes and human induced pluripotent stem cell-derived cardiomyocytes. CONCLUSIONS CIRKIL is a detrimental factor in I/R injury acting via regulating nuclear translocation of Ku70 and DNA double-strand breaks repair. Thus, CIRKIL might be considered as a novel molecular target for the treatment of cardiac conditions associated with I/R injury.
Collapse
Affiliation(s)
- Hongwen Xiao
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Mingyu Zhang
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Hao Wu
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.).,College of Pharmacy and Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin Medical University, P.R. China. (H.W., D.L., Q.H., Y.L.)
| | - Jiaxu Wu
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Xiaoxi Hu
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Xinyu Pei
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Danyang Li
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.).,College of Pharmacy and Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin Medical University, P.R. China. (H.W., D.L., Q.H., Y.L.)
| | - Lu Zhao
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Qi Hua
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.).,College of Pharmacy and Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin Medical University, P.R. China. (H.W., D.L., Q.H., Y.L.)
| | - Bo Meng
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Xiaowen Zhang
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Lili Peng
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Xiaoling Cheng
- Department of Medicinal Chemistry, Harbin Medical University, P.R. China. (X.C.)
| | - Zhuoyun Li
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Wanqi Yang
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Qi Zhang
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Yang Zhang
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| | - Yanjie Lu
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.).,College of Pharmacy and Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin Medical University, P.R. China. (H.W., D.L., Q.H., Y.L.)
| | - Zhenwei Pan
- Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, P.R. China. (H.X., M.Z., H.W., J.W., X.H., X.P., D.L., L.Z., Q.H., B.M., X.Z., L.P., Z.L., W.Y., Q.Z., Y.Z., Y.L., Z.P.)
| |
Collapse
|